FPR2-Binding Anti-Inflammatory Peptide for Immune-Sparing Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current anti-inflammatory treatments, particularly for chronic inflammatory and autoimmune diseases, often suppress normal immune responses, leading to side effects such as decreased immunity and secondary infections, necessitating a novel approach to safely control inflammatory responses.

Innovation Solution

A novel peptide that binds to the FPR2 receptor, regulating immune cell activity and inducing the resolution of inflammation, is developed for use in pharmaceutical compositions to treat immune diseases and cancer, and as an anti-inflammatory cosmetic.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Object-affected harmful factors

If current anti-inflammatory treatments are used to suppress inflammatory responses, then inflammatory symptoms are effectively controlled, but normal immune responses are inhibited leading to decreased immunity and secondary infections

Engineering Contradiction:

Improveinflammatory response controlVSAvoidimmune function

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The invention segments the inflammatory response control into two distinct phases: acute inflammation suppression and resolution promotion. The peptide specifically targets the resolution phase by activating FPR2 receptors, while leaving acute inflammation mechanisms intact. This segmentation allows selective modulation of inflammation without broad immune suppression.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The peptide acts as an intermediary substance that mediates the transition from acute inflammation to resolution phase. It binds to FPR2 receptors on immune cells, serving as a chemical messenger that triggers resolution mechanisms without directly suppressing the inflammatory cascade. This intermediary role enables precise control of inflammation timing and intensity.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Duration of action of stationary object

If broad-spectrum immunosuppressants are used for long-term treatment of chronic inflammatory diseases, then inflammatory symptoms are controlled, but side effects such as decreased immunity and secondary infections increase

Engineering Contradiction:

Improvelong-term treatment efficacyVSAvoidside effects

Core Design Contradiction:

Duration of action of stationary objectVSObject-generated harmful factors

Solution Approach 1:

Instead of suppressing inflammation through immunosuppression, the invention inverts the approach by actively promoting the resolution phase of inflammation. Rather than blocking inflammatory pathways, it stimulates the body's natural resolution mechanisms through FPR2 activation, thereby controlling chronic inflammation without immunosuppressive side effects.

Inventive Principle:

Principle #13The other way round (Inversion)

Solution Approach 2:

The invention changes the therapeutic parameter from broad immune suppression to specific resolution phase activation. By targeting FPR2 receptors and promoting lipid mediator production, the treatment shifts the inflammatory profile from sustained activation to active resolution, maintaining immune competence while controlling chronic inflammation.

Inventive Principle:

Principle #35Parameter changes

3Object-affected harmful factors

If existing anti-inflammatory strategies are used to strongly inhibit acute inflammatory responses, then inflammatory symptoms are effectively suppressed, but normal inflammatory responses are also inhibited causing various side effects

Engineering Contradiction:

Improveacute inflammatory response inhibitionVSAvoidnormal immune response

Core Design Contradiction:

Object-affected harmful factorsVSAdaptability or versatility

Solution Approach 1:

The invention introduces dynamic control of inflammation by timing-specific activation of resolution mechanisms. The peptide enables the immune system to naturally progress through acute inflammation and then actively transition to resolution, creating a dynamic rather than static anti-inflammatory effect. This preserves normal immune adaptability while providing effective symptom control.

Inventive Principle:

Principle #15Dynamics

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The peptide effectively inhibits inflammatory cytokines, improves disease severity scores in animal models, and inhibits tumor growth, demonstrating high FPR2 activation efficacy and selectivity, while reducing inflammatory responses.

Implementation Method 1

A novel peptide that binds to the FPR2 receptor, regulating immune cell activity and inducing the resolution of inflammation

Methodology Applied

Scientific EffectReceptor binding:

Implementation Method 2

The peptide effectively inhibits inflammatory cytokines, improves disease severity scores in animal models, and inhibits tumor growth

Methodology Applied

Scientific EffectCytokine inhibition:

Data Source

PatentUS20250361268A1Novel Anti-inflammatory peptide and use thereof

Publication Date: 2025.11.27 NOVACELL TECH

AI summary

The present invention relates to a novel immunoregulatory peptide having the ability to control inflammatory responses, and a use thereof. The peptide of the present invention may be useful in the treatment of inflammation, various immune diseases, or cancer, by regulating the activity of immune cells.